Fennec Pharmaceuticals (FENC) Panoramica del titolo
Fennec Pharmaceuticals Inc. opera come azienda biofarmaceutica in fase commerciale negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 6/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
FENC Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Fennec Pharmaceuticals Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$11.87 |
| Massimo di 52 settimane | US$13.25 |
| Minimo di 52 settimane | US$5.65 |
| Beta | 1.07 |
| Variazione di 1 mese | 19.90% |
| Variazione a 3 mesi | 19.06% |
| Variazione di 1 anno | 46.91% |
| Variazione a 3 anni | 49.68% |
| Variazione a 5 anni | 48.56% |
| Variazione dall'IPO | -89.53% |
Notizie e aggiornamenti recenti
Articolo di analisi • Aug 14
Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) just released its second-quarter report and things are looking bullish...Seeking Alpha • Aug 12
Fennec: The Turnaround Is Real, But The Stock Prices In Perfection (Downgrade)
Summary Fennec Pharmaceuticals has rebounded to near 52-week highs after PEDMARK drove the business to profitability, easing dilution fears. Despite 78% Y/Y net sales growth and a positive Q2 net income, the stock now trades at ~36x forward earnings for a single-asset business with no pipeline. PEDMARK's market exclusivity should last until 2033, but the company's lack of diversification and limited cash constrain its M&A and growth options. I downgrade Fennec to 'Sell,' citing a lack of margin of safety and a valuation that fully prices in perfect PEDMARK execution. Read the full article on Seeking AlphaRecent updates
Articolo di analisi • Aug 14
Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) just released its second-quarter report and things are looking bullish...Seeking Alpha • Aug 12
Fennec: The Turnaround Is Real, But The Stock Prices In Perfection (Downgrade)
Summary Fennec Pharmaceuticals has rebounded to near 52-week highs after PEDMARK drove the business to profitability, easing dilution fears. Despite 78% Y/Y net sales growth and a positive Q2 net income, the stock now trades at ~36x forward earnings for a single-asset business with no pipeline. PEDMARK's market exclusivity should last until 2033, but the company's lack of diversification and limited cash constrain its M&A and growth options. I downgrade Fennec to 'Sell,' citing a lack of margin of safety and a valuation that fully prices in perfect PEDMARK execution. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jun 15
FENC: Expanding Cisplatin Tumor Coverage Will Support Future Bullish Earnings Multiple
Analysts have raised their price target on Fennec Pharmaceuticals to $16 from $13, citing growing Pedmark adoption across new and existing accounts, with demand coming from three core tumor types. What's in the News Four PEDMARK clinical abstracts accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on multiple tumor types and age groups.Aggiornamento narrativa • Jun 01
FENC: Expanding Cisplatin Cancer Use Will Support Future Bullish Earnings Multiple
Analysts have lifted their price target on Fennec Pharmaceuticals stock to $16 from $13, pointing to building Pedmark adoption across core tumor types, including testicular, cervical, and head and neck cancers, as the key driver behind the change. What's in the News Four new PEDMARK abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on multiple tumor types and patient populations.Articolo di analisi • May 17
We're Not Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Aggiornamento narrativa • May 14
FENC: Expanding Cisplatin Ototoxicity Protection Use Will Support Future Bullish Earnings Multiple
Analysts have maintained their $18.00 price target on Fennec Pharmaceuticals, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that leave their overall valuation view unchanged. What's in the News Four abstracts on PEDMARK are set to be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on cisplatin related hearing loss and real world outcomes in patients receiving platinum based chemotherapy (Key Developments).Aggiornamento narrativa • Apr 25
FENC: Expanding Cisplatin Ototoxicity Use Should Support Future Bullish Earnings Multiple
Analysts have adjusted their price target on Fennec Pharmaceuticals to $18.00, with the change supported by updated assumptions around revenue growth, profit margins, and a future P/E of about 12.8, in line with a recently bullish initiation from Street research. Analyst Commentary Bullish analysts are framing the updated US$18.00 price target as consistent with expectations for Fennec Pharmaceuticals to execute against current revenue and margin assumptions while trading on a P/E of about 12.8. These views generally point to a setup where, if the company delivers on its plan, the current valuation case remains intact and could support the new target level.Aggiornamento narrativa • Apr 10
FENC: Cisplatin Ototoxicity Niche Will Support Future Bullish Earnings Multiple
Analysts have raised their price target on Fennec Pharmaceuticals to $18.00, supported by updated assumptions on revenue growth, profit margin and future P/E, and underpinned by a recent bullish initiation from B. Riley that reflects growing confidence in the company’s outlook.Aggiornamento narrativa • Mar 27
FENC: Cisplatin Ototoxicity Niche Will Underpin Future Supportive Care Upside
Analysts have reaffirmed an $18 price target for Fennec Pharmaceuticals, highlighting supportive research that emphasizes Pedmark's role as a unique, approved option in oncology supportive care. They are also reassessing assumptions related to future revenue growth, profit margins and P/E expectations.
Aggiornamento narrativa • Mar 11
FENC: Single Oncology Supportive Care Asset Will Drive Future Upside Potential
Narrative Update: Fennec Pharmaceuticals Analysts have lifted their price target on Fennec Pharmaceuticals from $14.00 to about $15.33, citing a richer revenue outlook, higher anticipated profit margins, and a willingness to apply a lower future P/E multiple. They highlight Pedmark's position as a unique, FDA approved option in oncology supportive care, with U.S. peak sales potential referenced above $300m.Aggiornamento narrativa • Feb 25
FENC: Cisplatin Ototoxicity Niche Will Support Future Oncology Care Upside
Analysts are reiterating an $18 price target for Fennec Pharmaceuticals. They point to updated assumptions that include slightly lower discount rates, higher projected revenue growth and profit margins, and a modestly lower future P/E, supported by recent bullish initiations that highlight Pedmark's role as a unique oncology supportive care opportunity.Aggiornamento narrativa • Feb 10
FENC: Cisplatin Ototoxicity Niche Will Drive Future Supportive Care Upside
Analysts have reiterated a US$18 price target on Fennec Pharmaceuticals, supported by their view that Pedmark offers a unique, only-approved option in oncology supportive care, with what they describe as realistic peak U.S. sales potential above US$300m. Analyst Commentary Recent coverage has centered on Pedmark as a key driver for Fennec's equity story, with bullish analysts highlighting its role as the only approved agent for reducing the risk of cisplatin induced ototoxicity in oncology supportive care.Aggiornamento narrativa • Jan 26
FENC: Cisplatin Ototoxicity Leadership And New Studies Will Support Strong Future Upside
Narrative Update Analysts are reaffirming a US$18 price target on Fennec Pharmaceuticals, pointing to Pedmark's role as the only approved agent for reducing cisplatin induced ototoxicity and noting that they view U.S. peak sales potential above US$300m as realistic. Analyst Commentary Bullish analysts are highlighting Fennec Pharmaceuticals as a focused oncology supportive care story, built around Pedmark as an intravenous formulation of sodium thiosulfate for reducing the risk of cisplatin induced ototoxicity.Aggiornamento narrativa • Jan 12
FENC: Unique Oncology Supportive Care Opportunity Will Drive Stronger Future Upside Potential
Narrative Update Overview Our fair value estimate for Fennec Pharmaceuticals edges up from $17 to $18 per share, reflecting analysts' view that Pedmark offers a unique oncology supportive care opportunity with U.S. peak sales potential cited north of $300 million and supports using a slightly higher revenue growth outlook, modestly stronger profit margins, and a lower future P/E multiple. Analyst Commentary Bullish analysts are centering their thesis on Pedmark as a differentiated oncology supportive care product, and that view is shaping how they think about valuation, execution risk, and long term growth potential.Aggiornamento narrativa • Dec 27
FENC: Expanded Adult Study Will Drive Stronger Future Upside Potential
Analysts have nudged their price target on Fennec Pharmaceuticals modestly higher to reflect slightly faster expected revenue growth, marginally improved profit margins, and a marginally lower projected future price to earnings multiple, supporting a fair value estimate of $17.00 per share. What's in the News Planned City of Hope investigator sponsored study will evaluate PEDMARK for preventing cisplatin induced hearing loss in adult men with stage II III metastatic testicular germ cell tumors, expanding its potential use beyond pediatrics (company announcement).Aggiornamento narrativa • Dec 13
FENC: Expanded Hearing Loss Indication Will Drive Stronger Future Upside Potential
Analysts have raised their price target on Fennec Pharmaceuticals from 15 dollars to 17 dollars, citing updated assumptions for discount rates, growth, profitability, and valuation multiples that, despite being more conservative on margins and revenue growth, still imply a higher fair value. What's in the News City of Hope to launch an investigator sponsored study of PEDMARK in adult men with stage II III metastatic testicular germ cell tumors to prevent cisplatin induced hearing loss, expanding potential use beyond pediatrics (company announcement) Positive topline results reported from the Phase 2/3 STS J01 trial in Japan evaluating PEDMARK for reducing cisplatin induced ototoxicity in pediatric and AYA patients, with Fennec planning to pursue Japanese registration and potential partnering or licensing deals (company announcement) Completed 35 million dollar follow on equity offering of 4,666,667 common shares at 7.50 dollars per share, bolstering the balance sheet for commercialization and development initiatives (financing filing) Announced a non brokered private placement of 670,000 common shares at 7.50 dollars per share for expected gross proceeds of 5.0 million dollars, with closing targeted for November 17, 2025 (financing announcement) Lock up agreements put in place on over 28 million common shares and various equity linked awards through February 12, 2026, limiting insider and holder sales for 91 days after the November 13, 2025 offering (offering documentation) Valuation Changes Fair value estimate increased from 15 dollars to 17 dollars per share, implying a modest upward revision to intrinsic value despite more conservative operating assumptions.Articolo di analisi • Apr 24
Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price Is Matching Sentiment Around Its Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) may be sending very bullish...Articolo di analisi • Mar 13
US$12.60: That's What Analysts Think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Is Worth After Its Latest Results
Shareholders might have noticed that Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) filed its full-year result this time...Articolo di analisi • Nov 24
Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified
Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) shareholders are no doubt pleased to see that the share price has bounced...Articolo di analisi • Oct 04
Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 2.5x Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) is...
Nuova narrativa • Sep 28
Jeff Hackman's Leadership And PEDMARK's Launch Promise Robust Revenue Surge
Introduction of PEDMARK and strategic partnerships aim to boost net revenues through expanded patient access and improved distribution.Articolo di analisi • Aug 15
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Today is shaping up negative for Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) shareholders, with the analysts delivering...Articolo di analisi • Jul 16
Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Rendimenti per gli azionisti
| FENC | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 0.3% | 6.2% | -0.8% |
| 1Y | 46.9% | 46.3% | 20.5% |
Ritorno vs Industria: FENC ha superato il US Biotechs che ha restituito 46.3 % nell'ultimo anno.
Rendimento vs Mercato: FENC ha superato il mercato US che ha restituito 20.5 % nell'ultimo anno.
Volatilità dei prezzi
| FENC volatility | |
|---|---|
| FENC Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: FENC non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 9% ) di FENC è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1996 | 35 | Jeff Hackman | www.fennecpharma.com |
Fennec Pharmaceuticals Inc. opera come azienda biofarmaceutica in fase commerciale negli Stati Uniti. Il prodotto candidato dell'azienda comprende PEDMARK, una formulazione di tiosolfato di sodio per la prevenzione dell'ototossicità indotta dal cisplatino nei pazienti pediatrici. L'azienda commercializza i suoi prodotti attraverso specialisti regionali di oncologia pediatrica e contatti medico-scientifici.
Fennec Pharmaceuticals Inc. Riepilogo dei fondamenti
| FENC statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$416.25m |
| Utili (TTM) | -US$3.25m |
| Ricavi(TTM) | US$59.22m |
7.0x
Rapporto P/S-128.1x
Rapporto P/EFENC è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| FENC Conto economico (TTM) | |
|---|---|
| Ricavi | US$59.22m |
| Costo del fatturato | US$3.72m |
| Profitto lordo | US$55.51m |
| Altre spese | US$58.76m |
| Utili | -US$3.25m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.093 |
| Margine lordo | 93.73% |
| Margine di profitto netto | -5.49% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato FENC nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/19 14:29 |
| Prezzo dell'azione a fine giornata | 2026/08/19 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Fennec Pharmaceuticals Inc. è coperta da 10 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Naureen Quibria | Capital One Securities, Inc. |